Vanda amends Rights Agreement to exempt BlackRock from poison pill up to 20% ownership

Vanda Pharmaceuticals Inc.

Amendment adds BlackRock and its managed funds as 'Exempt Person' under the Rights Agreement.
BlackRock may acquire up to 20% of Vanda's common stock without triggering the poison pill.
Exempt status can be revoked immediately if BlackRock breaches representations or conditions.
The Board deems the amendment desirable based on BlackRock's representations and warranties.

item 1.01 item 3.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Vanda Pharmaceuticals Inc. amended Amendment No. 1 with Equiniti Trust Company, LLC (effective 2024-05-03).

Action: amendment
Counterparty: Equiniti Trust Company, LLC
Effective: 2024-05-03

Exact text from the filing

On May 3, 2024, Vanda Pharmaceuticals Inc., a Delaware corporation (the “Company”), entered into Amendment No. 1 (the “Amendment”) to that certain Rights Agreement, dated as of April 17, 2024 (the “Rights Agreement”), by and between the Company and Equiniti Trust Company, LLC, a limited trust company organized under the laws of the State of New York, as rights agent.

View on SEC.gov

Browse all material agreements →

Vanda Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-130668

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.